Trends in Cancer
短名 | Trends. Cancer. |
Journal Impact | 14.21 |
国际分区 | ONCOLOGY(Q1) |
期刊索引 | SCI Q1中科院 1 区 |
ISSN | 2405-8025, 2405-8033 |
h-index | 90 |
国内分区 | 医学(1区)医学肿瘤学(2区) |
Top期刊 | 是 |
TRENDS IN CANCER 是 TRENDS 评论期刊的新成员,提供简洁且引人入胜的专家评论文章,讨论关键的前沿研究主题和快速变化的癌症发现和医学领域的前沿进展。该杂志为多学科信息、讨论和教育提供了一个独特的平台,对科学家、临床医生和政策制定者以及患者和倡导者都很有价值。基础、转化和临床发现、行业研发、技术和创新、伦理或癌症政策和资金的最新机遇、挑战和潜在影响均以权威但便于读者阅读的形式呈现和辩论。
期刊主页投稿网址涉及主题 | 生物医学遗传学内科学癌症化学生物化学癌症研究基因免疫学细胞生物学病理免疫系统计算生物学计算机科学生物信息学 |
出版信息 | 出版商: Cell Press,出版周期: ,期刊类型: journal |
基本数据 | 创刊年份: 2015,原创研究文献占比: 0.00%,自引率:0.70%, Gold OA占比: 42.59% |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Trends in cancer imaging
2024-9-1
Environmental pollutants and bad bugs work hand in glove
2024-9-1
Epigenetic control of immunoevasion in cancer stem cells
2024-9-1
Scaling data toward pan-cancer foundation models
2024-9-1
CD4+ T cells in antitumor immunity
2024-9-1
Advisory Board and Contents
2024-9-1
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes
2024-9-1
Subscription & copyright page
2024-9-1
Bispecific antibodies: advancing precision oncology
2024-8-1
Future perspectives on engineered T cells for cancer
2024-8-1
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy
2024-8-1
Advisory Board and Contents
2024-8-1
Advances in exosomes utilization for clinical applications in cancer
2024-8-1
CFTR and colorectal cancer susceptibility: an urgent need for further studies
2024-8-1
Mechanisms governing lineage plasticity and metabolic reprogramming in cancer
2024-8-1
Reconceptualizing mental health in cancer survivorship
2024-8-1
Chromatin as an old and new anticancer target
2024-8-1
The origin of novel traits in cancer
2024-8-1
Watch your clock: it matters for immunotherapy
2024-8-1
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights
2024-8-1
Subscription & copyright page
2024-8-1
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells
2024-8-1
Biosocial determinants inform on enduring cancer disparities
2024-8-1
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity
2024-8-1
Targeting cancer stem cells in multiple myeloma
2024-7-5
PARPi, BRCA, and gaps: controversies and future research
2024-7-1
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations
2024-7-1
Metastatic hormone-naïve prostate cancer: a distinct biological entity
2024-7-1
Towards enhancing the predictive value of the microbiota for cancer immunotherapy
2024-7-1
Advisory Board and Contents
2024-7-1
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer
2024-7-1
Current landscape of CD3 bispecific antibodies in hematologic malignancies
2024-7-1
Oncology-respirology: a discipline in dire need
2024-7-1
Emerging and extensive clonal evolution in the pancreas
2024-7-1
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development
2024-7-1
A new BRAF inhibitor breaks resistance barriers
2024-7-1
Transcriptomic subtyping of gastrointestinal malignancies
2024-7-1
Mind the gap: why we need to consider teenage and young adult cancers across the research pipeline
2024-7-1
Subscription & copyright page
2024-7-1
Precision oncology: current and future platforms for treatment selection
2024-7-1
Next-generation cancer vaccines and emerging immunotherapy combinations
2024-7-1
B7-H3: a robust target for immunotherapy in prostate cancer
2024-6-4
Puzzling phenomenon: adult-onset cancer predisposition and pediatric cancer
2024-6-1
Exploiting the metabolic vulnerability of circulating tumour cells
2024-6-1
Intracranial CAR-T cell delivery in glioblastoma patients
2024-6-1
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
2024-6-1
Advisory Board and Contents
2024-6-1
Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy
2024-6-1
Subscription & copyright page
2024-6-1
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
2024-5-31
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远